Navigation Links
Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
Date:11/3/2010

eins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and their applications in the treatment of disease. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological dev
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... A novel combination of microscopy and data processing has ... National Laboratory an unprecedented look at the surface of ... properties. , The research team led by ORNL,s ... a perovskite manganite, a complex material that exhibits dramatic ... surface behavior could benefit researchers who are interested in ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... October 1 , - "Expert Consult" ... Content is Always Current, Elsevier, the ... the publication of the 40th edition of ... Gray,s Anatomy: The Anatomical Basis of Clinical,Practice ...
... product design and development, manufacture, and distribution ... ... 1 Cylex has announced receipt of,certification to ISO ... Canadian Medical Devices Conformity Assessment,System (CMDCAS). These certifications signify ...
... Sept. 30 NxStage Medical,Inc. (Nasdaq: NXTM ), ... Jeffrey H. Burbank, Chief Executive Officer,and Robert S. Brown, ... Healthcare Focus Conference on October 6, 2008 at Le ... is scheduled for Monday, October 6th at,2:30 p.m. ET. ...
Cached Biology Technology:New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 2New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 3Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... As the human population increases, so too do the ... issue of International Journal of Plant Sciences , ... Sarah Assmann explores how the responses to environmental stresses ... possible approaches to addressing growing human demand for crop ...
... despite the yuck factor, have captured the hearts of two ... team that this week is publishing the leech,s complete genome ... Weisblat, a UC Berkeley professor of molecular and cell biology ... sequencing initiative that has targeted a variety of animals in ...
... the quest to find the easiest and fastest way to ... In an article published in Frontiers in Microbiology on ... polymerase chain reaction (PCR) system to discover specific gene targets ... show that assays performed using this PCR system are rapid, ...
Cached Biology News:Can observations of a hardy weed help feed the world? 2What do leeches, limpets and worms have in common? Now, a sequenced genome 2What do leeches, limpets and worms have in common? Now, a sequenced genome 3USDA explores using novel genetic labs for faster detection of E. coli 2
Mouse anti human pro-Relaxin-2...
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... polyclonal to ErbB 2 - BSA ... for all tested applications). ... conjugated to KLH, corresponding to C ... c-ErbB2 Entrez GeneID: ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Biology Products: